Sosei Heptares - Investor and Press Conference on Today’s Announcement Regarding the Acquisition and License Transaction with Idorsia Jul 20, 2023 02:31AM
Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company Jul 20, 2023 02:30AM
Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results Jul 11, 2023 03:00AM
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia Jul 2, 2023 08:23PM
Sosei Heptares Provides Update on Lotiglipron Development Jun 26, 2023 06:40PM


May 12, 2023 02:30AM Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
Aug 12, 2021 03:00AM Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021
Jul 6, 2021 03:00AM Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
May 19, 2021 03:00AM Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
Mar 11, 2021 04:00AM Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
Feb 12, 2021 03:00AM Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020
Feb 1, 2021 02:00AM Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
Jan 12, 2021 03:00AM Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target
Jan 5, 2021 02:00AM Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
Dec 22, 2020 03:00AM Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
Dec 20, 2020 07:01PM Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
Dec 1, 2020 03:05AM Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
Nov 20, 2020 04:05AM Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
Nov 11, 2020 02:55AM Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months ended 30 September 2020
Sep 3, 2020 04:57AM Sosei Heptares Appoints Top-Ranked Investment Analyst Hironoshin Nomura as Senior Vice President, Investor Relations and Corporate Strategy
Jul 16, 2020 02:47AM Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds
Oct 3, 2018 07:05AM Nomura/Instinet Downgrades Sosei Group Corp. (4565:JP) (SOLTF) to Neutral